Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy/Experiment 22/Signature 2

EditHistoryDelete

Mark reviewed

Your review change was submitted

Needs review

Curated date: 2024/11/10

Curator: KateRasheed

Revision editor(s): KateRasheed

Source: Additional file 11: Figure S11

Description: Differentially abundant between the Naive group and RZ (R-Rifampin, Z-Pyrazinamide) treatment group.

Abundance in Group 1: decreased abundance in RZ (R-Rifampin, Z-Pyrazinamide)

NCBI	Quality Control	Links
Marvinbryantia
Acetivibrio
Acetanaerobacterium
Christensenella
Sporobacter
Ethanoligenens
Pseudobutyrivibrio
Stomatobaculum
Dorea
Butyricicoccus
Anaerosporobacter
Eisenbergiella
Mucispirillum
Tyzzerella
Clostridium
Anaerotruncus
Enterorhabdus
Arthrobacter
Guggenheimella
Eubacteriales Family XIII. Incertae Sedis
Flavonifractor
Turicibacter
Intestinimonas
Robinsoniella
Pseudoflavonifractor
Ruminococcus
Hydrogenoanaerobacterium
Oxobacter
Acetatifactor
Roseburia
Pseudobacteroides
Romboutsia
unclassified Pelotomaculum
Dysgonomonas
Erysipelotrichaceae
Oscillibacter
Coprobacter
Parabacteroides
Lachnospiraceae

Revision editor(s): KateRasheed